FOSTER ® is a drug based on Beclometasone dipropionate and Formoterol fumarate dihydrate.
THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive syndromes of the respiratory tract.
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications FOSTER ® - Beclometasone + Formoterol
FOSTER ® is indicated for the treatment of asthma inadequately responsive to corticosteroid therapy alone or with short-acting B2 adrenergic agonists.
Mechanism of action FOSTER ® - Beclometasone + Formoterol
FOSTER ® is a medicinal specialty used in the treatment of asthma, consisting of a corticosteroid Beclometasone and a long-acting Beta 2 adrenergic agonist, Formoterol.
The aforementioned active ingredients, despite having very different biological properties, contribute to the control of the obstructive respiratory symptomatology present during asthmatic pathology.
More precisely, Beclomethasone, by actively controlling the secretion of inflammatory cytokines by the respiratory mucosa, reduces the degree of airway inflammation determining, among other things, a prompt regression of the obstructive and congestive symptomatology that characterizes this pathology; Formoterol on the other hand, by binding the Beta 2 adrenergic receptors, expressed by bronchial smooth muscle, limits the contractile degree, restoring the normal patency of the respiratory tract.
The different pharmacokinetic characteristics of the two active ingredients allow the establishment of biological activity very quickly, just minutes after administration, which lasts for several hours after inhalation.
Studies carried out and clinical efficacy
BECLOMETASONE FORMOTEROL IN THE OXIDATIVE DAMAGE PROTECTION
Eur J Pharmacol. 2013 Oct 15; 718 (1-3): 418-27. doi: 10.1016 / j.ejphar.2013.08.001. Epub 2013 Aug 19.
Interesting experimental study that demonstrates how the association between Beclometasone and Formoterol can reduce the activation of oxidative mechanisms in cells of the bronchial epithelium subjected to cigarette smoke exposure, protecting them from possible oxidative damage.
FORMOTEROLO AND BECLOMETASONE EXTRA FINE
Pulm Pharmacol Ther. 2013 Jun 14. pii: S1094-5539 (13) 00132-6.
Study that shows how the administration of Formoterol and Beclometasone in extra fine particles can determine a clear improvement in the symptoms present in asthma conditions, determining a better ability to penetrate the bronchial epithelium.
BECLOMETASONE FORMOTEROL IN COPD THERAPY
Int J Chron Obstruct Pulmon Dis. 2011; 6: 503-9. doi: 10.2147 / COPD.S23746. Epub 2011 Oct 4.
An interesting work that demonstrates that maintenance therapy with Formoterol and extra fine Beclometasone may determine a marked improvement in dyspnea in patients with chronic obstructive pulmonary disease, thus leading to a marked improvement in symptoms.
Method of use and dosage
FOSTER ®
Pressurized solution for inhalation of 100 mcg of Beclometasone dipropionate and 6 mcg of Formoterol fumarate dihydrate.
The therapeutic scheme varies considerably from patient to patient based on the characteristics of general health and the severity of his clinical picture.
The doctor should therefore set this therapy in a highly specific manner, taking care to define for each case the minimum dosage necessary to guarantee a good control of the symptoms.
In any case, the maximum dosage should never exceed 4 daily inhalations.
Warnings FOSTER ® - Beclometasone + Formoterol
The therapy with FOSTER ® must necessarily be preceded and supervised by medical personnel, in order to assess its prescription appropriateness, efficacy and safety.
It is also necessary to consider that therapy with FOSTER ® is not adequate for the treatment of acute asthmatic crisis.
Particular caution should obviously be reserved for patients suffering from cardiovascular pathologies, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, for which an aggravation of the clinical picture could be observed.
In order to limit the appearance of clinically relevant side effects, it would be appropriate for the doctor to identify the minimum effective dose to guarantee a control of the symptoms and to inform the patient of all the potential side effects related to the therapy, so that the latter can recognize them promptly and alarm your doctor in time.
Although the systemic exposure to the two active ingredients is limited, it would be appropriate for the doctor to also check for the possible occurrence of systemic adverse reactions.
FOSTER ® is prohibited in and out of the race.
It is recommended to keep the medicine out of the reach of children.
PREGNANCY AND BREASTFEEDING
The aforementioned contraindications to the use of FOSTER ® also extend to pregnancy and the subsequent period of breastfeeding, given the absence of studies able to fully characterize the safety profile of the two active ingredients contained in the health drug of fetus and infant.
Interactions
The patient receiving FOSTER ® should avoid the simultaneous intake of non-selective Beta 2 agonists and beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalemia.
Contraindications FOSTER ® - Beclometasone + Formoterol
The use of FOSTER ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients suffering from severe cardiopathies, glaucoma, prostatic hypertrophy and urinary retention syndrome or intestinal obstruction:
Undesirable effects - Side effects
FOSTER ® therapy, especially when prolonged over time or carried out on particularly susceptible patients, could lead to pharyngitis, headache, cough, hypokalemia, muscle spasms, throat irritations, dysphonia and oral candidiasis.
Fortunately, the incidence of clinically more relevant side effects such as skin rash, hypersensitivity, urticaria, angioedema and cardiac manifestations is rarer.
Note
FOSTER ® is a prescription-only drug.
